Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 461

Sort by

Sort Order Select

Journal Articles

Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure

Michael W. Henderson, Erica M. Sparkenbaugh, Shaobin Wang, Anton Ilich, Denis F. Noubouossie, Reiner Mailer, Thomas Renné, Matthew J. Flick, James P. Luyendyk, Zu-Lin Chen, Sidney Strickland, R. Todd Stravitz, Keith R. McCrae, Nigel S. Key, Rafal Pawlinski

Blood (2021) 138 (3): 259–272.

https://doi.org/10.1182/blood.2020006198

Published: 2021

Includes: Supplemental data

Journal Articles

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

Matthew Lunning, Julie Vose, Loretta Nastoupil, Nathan Fowler, Jan A. Burger, William G. Wierda, Marshall T. Schreeder, Tanya Siddiqi, Christopher R. Flowers, Jonathon B. Cohen, Peter Sportelli, Hari P. Miskin, Michael S. Weiss, Susan O’Brien

Blood (2019) 134 (21): 1811–1820.

https://doi.org/10.1182/blood.2019002118

Published: 2019

Includes: Supplemental data

Journal Articles

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Maureen M O'Brien, MD, Lingyun Ji, PhD, Nirali N. Shah, MD, Susan R. Rheingold, MD, Deepa Bhojwani, MD, Joanna S. Yi, MD, Constance M. Yuan, MD PhD, Andrew C Harris, MD, Patrick A. Brown, MD, Michael J. Borowitz, MD PhD, Olga Militano, PharmD, Meenakshi Devidas, PhD, Elizabeth A. Raetz, MD, Lia Gore, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_1): 741.

https://doi.org/10.1182/blood-2019-128977

Published: 2019

Journal Articles

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naval G. Daver, MD, Pau Montesinos, MD PhD, Daniel J. DeAngelo, MD, Eunice S. Wang, MD, Nikolaos Papadantonakis, MDPhDMSc, Eric Deconinck, MD PhD, Harry P. Erba, MD PhD, Naveen Pemmaraju, MD, Andrew A. Lane, MD PhD, David A. Rizzieri, MD, Kendra L. Sweet, MD, Giovanni Martinelli, Corrado Tarella, MD, Elisabetta Todisco, MD PhD, Marina Y Konopleva, MD PhD, Callum M. Sloss, PhD, Kerry Culm-Merdek, PhD, Patrick A. Zweidler-McKay, MD PhD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 734.

https://doi.org/10.1182/blood-2019-128648

Published: 2019

Journal Articles

Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLL

Deepti Gadi, PhD, Siddha Kasar, PhD, Alec Griffith, BS, Pui Yan Chiu, Svitlana Tyekucheva, PhD, Vanessa Rai, BS, Alexander R. Vartanov, MD, Stacey M. Fernandes, BS, Yang Pan, PhD, James A Lederer, PhD, Barbara Sherry, PhD, Jennifer R. Brown, MD PhD

Blood (2019) 134 (Supplement_1): 1745.

https://doi.org/10.1182/blood-2019-122961

Published: 2019

Journal Articles

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Bjørn T. Gjertsen, MD PhD, Andreas Hochhaus, MD, Gianantonio Rosti, MD, Justin M. Watts, MD, Guillermo Ortí, Philipp le Coutre, MD, Eric Leip, PhD, Andrea Viqueira, MD, Jorge E. Cortes, MD, Frank Giles, MD, Carlo Gambacorti-Passerini, MD

Blood (2019) 134 (Supplement_1): 1639.

https://doi.org/10.1182/blood-2019-121815

Published: 2019

Journal Articles

Survival Benefits from Antifungal Prophylaxis and a Dedicated Inpatient Malignant Hematology Service during Induction Chemotherapy for Acute Myeloid Leukemia

Andrew Hsu, MD, Robert Matera, MD, John L. Reagan, MD, Dimitrios Farmakiotis, MD

Blood (2019) 134 (Supplement_1): 3436.

https://doi.org/10.1182/blood-2019-122264

Published: 2019

Journal Articles

High Molecular Weight Kininogen but Not Factor XII Deficiency Attenuates Acetaminophen-Induced Liver Injury in Mice

Michael Wayne Henderson, MSc, Erica Sparkenbaugh, PhD BS, Denis Noubouossie, MD PhD, Reiner Mailer, Thomas Renne, MD PhD, Keith R McCrae, MD, Nigel S. Key, MBChB, FRCP, Rafal Pawlinski, PhD

Blood (2019) 134 (Supplement_1): 3621.

https://doi.org/10.1182/blood-2019-127206

Published: 2019

Journal Articles

Telomere Elongation and Clinical Improvement in Telomeropathy Patients: A Prospective Clinical Trial of Nandrolone in Telomeropathies

Diego V Clé, MD PhD, Luiz Fernando Catto, MD, Luiz Guilherme Darrigo, PhD, Elvis Valera, Fernanda Gutierrez-Rodrigues, PhD, Flavia S. Donaires, PhD, André Pinto, Renan C. Albino, Bárbara Santana, Jose Baddini-Martinez, MD PhD, Rodrigo T. Calado, MD PhD

Blood (2019) 134 (Supplement_1): 2501.

https://doi.org/10.1182/blood-2019-130844

Published: 2019

Journal Articles

Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase

Hanny Al-Samkari, MD, Kavita Aggarwal, PharmD, Michael Vredenburg, PhD, Wei Tian, PhD, Lee F. Allen, MD PhD

Blood (2019) 134 (Supplement_1): 2356.

https://doi.org/10.1182/blood-2019-131215

Published: 2019

Journal Articles

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

Cecile Tomowiak, MD, Kristell Desseaux, Stéphanie Poulain, MD PhD, Charles Herbaux, MD, Aurore Perrot, MD PhD, Beatrice Mahe, MD, Pierre Morel, MD, Olivier Tournilhac, Stephane Lepretre, MD, Thérèse Aurran, MD, Bruno Villemagne, MD, Olivier Casasnovas, MD, Delphine Nollet, Brigitte Dreyfus, MD, Sylvie Chevret, MD PhD, Veronique Leblond, MD PhD

Blood (2019) 134 (Supplement_1): 346.

https://doi.org/10.1182/blood-2019-122826

Published: 2019

Journal Articles

Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation

Glen A Kennedy, MBBS FRACP FRCPA, Siok-Keen Tey, MBBS,PhDFRACP,FRCPA, Cameron Curley, MBBS, FRACP, FRCPA, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Ashish Misra, MBBS, FRACP, Elango Subramoniapillai, MBBS, FRACP, James Morton, MBBS, FRACP, FRCPA, Simon Durrant, FRCP,FRCPath,MBBS, Andrea S Hendon, MBBS, PhD FRACP, FRCPA, John Moore, MDFRACP,FRCPA, David Ritchie, MD PhD, David Gottlieb, MBBS, MD FRACP, FRCPA, Julian Cooney, FRACP,FRCPA,MBBS,, Luke Buizen, BSc (Hons), MSc, Sanjoy K Paul, PhD, Geoff R. Hill, MD

Blood (2019) 134 (Supplement_1): 368.

https://doi.org/10.1182/blood-2019-126285

Published: 2019

Journal Articles

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Pier Luigi Zinzani, MD, Armando Santoro, Luigina Mollica, MD FRCPC, PhD, Sirpa Leppä, MD PhD, George A Follows, MD PhD, Georg Lenz, MD, Won Seog Kim, MD PhD, Arnon Nagler, MD MSc, Panayiotis Panayiotidis, MD, Judit Demeter, MD PhD Dr. Sci, Franck Morschhauser, MD, Javier Munoz, MD MS, FACP, Ashok Miriyala, MD, Alice Benson, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Martin Dreyling, MD

Blood (2019) 134 (Supplement_1): 4009.

https://doi.org/10.1182/blood-2019-131779

Published: 2019

Journal Articles

Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction

Thomas Luft, MD PhD, Hao Dai, Aleksandar Radujkovic, MD, David Schult, Joshua Majer-Lauterbach, Olga Blau, MD PhD, Lars Bullinger, Sihe Jiang, Carsten Müller-Tidow, MD, Peter Dreger, Olaf Penack, MD

Blood (2019) 134 (Supplement_1): 4487.

https://doi.org/10.1182/blood-2019-124284

Published: 2019

Journal Articles

Early Organ Toxicity Following Allogeneic Hematopoietic Stem Cell Transplantation Differs By Conditioning Regimen

Joshua A Fein, MD, Avichai Shimoni, MD, Ivetta Danylesko, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Guy Chowers, MD, Zachary Cohen, Arnon Nagler, MD MSc, Roni Shouval

Blood (2019) 134 (Supplement_1): 4489.

https://doi.org/10.1182/blood-2019-126325

Published: 2019

Journal Articles

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, MDMPhil, Megan Othus, PhD, Mary-Elizabeth M. Percival, MD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Kelda M. Gardner, PA-C, Sioban B. Keel, MD, Tejaswini M. Dhawale, MD, Vivian G. Oehler, MD, Janis L. Abkowitz, MD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Kaysey F. Orlowski, Alice Woo, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 3892.

https://doi.org/10.1182/blood-2019-126009

Published: 2019

Journal Articles

Efficacy and Safety of Daily All-Trans Retinoic Acid Monotherapy As Maintenance Therapy for Acute Promyelocytic Leukemia

Yoo Jin Lee, MD PhD, Seo-Yeon Ahn, MD, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD, Ji Hyun Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3898.

https://doi.org/10.1182/blood-2019-125671

Published: 2019

Journal Articles

Oral Arsenic Trioxide in Front Line Therapy for Acute Promyelocytic Leukemia. A Prospective Costa Rican Study

Mariela Rodriguez, MD, Ronald Rojas, Alejandra Vargas, MD, Miguel Angel Rodriguez, MD, Claudia Garcia, MD, Juliana Esquivel, MD, Jose Gerardo Rojas, MD, Willem Bujan Boza, MD

Blood (2019) 134 (Supplement_1): 3838.

https://doi.org/10.1182/blood-2019-122627

Published: 2019

Journal Articles

Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Patients from the Learn Consortium

Joanna S. Yi, MD, Tiffany Chambers, MPH, Kelly D Getz, Tamara P. Miller, MDMSc, Evanette Burrows, MPH, Marla Daves, MD, Philip J. Lupo, PhD MPH, Michael E. Scheurer, PhD MPH, Richard Aplenc, MD PhD, Karen R. Rabin, MD PhD, Maria Monica J. Gramatges, MD PhD

Blood (2019) 134 (Supplement_1): 3814.

https://doi.org/10.1182/blood-2019-123992

Published: 2019

Journal Articles

Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic Leukemia

Ryan J. Daley, PharmD, Sridevi Rajeeve, MD, Charlene C. Kabel, PharmD, Jeremy J. Pappacena, PharmD, BCOP, Sarah E. Stump, PharmD, BCPS, BCOP, Jessica A. Lavery, MS, Martin S. Tallman, MD, Mark B. Geyer, MD, Jae H. Park, MD

Blood (2019) 134 (Supplement_1): 3816.

https://doi.org/10.1182/blood-2019-124727

Published: 2019

NARROW

Plasmin-mediated cleavage of high-molecular-weight kininogen contributes to acetaminophen-induced acute liver failure

Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia

A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621

Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Imbalance in T Cell Subsets Triggers the Autoimmune Toxicity of PI3K Inhibitors in CLL

Cross-Intolerance with Bosutinib after Prior Tyrosine Kinase Inhibitors in Patients with Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study

Survival Benefits from Antifungal Prophylaxis and a Dedicated Inpatient Malignant Hematology Service during Induction Chemotherapy for Acute Myeloid Leukemia

High Molecular Weight Kininogen but Not Factor XII Deficiency Attenuates Acetaminophen-Induced Liver Injury in Mice

Telomere Elongation and Clinical Improvement in Telomeropathy Patients: A Prospective Clinical Trial of Nandrolone in Telomeropathies

Long-Term Response Rates in Patients with Chronic Immune Thrombocytopenia Treated with Avatrombopag: Additional Analyses from a Phase 3 Study and Its Extension Phase

Open Label Non-Randomized Phase II Study Exploring «Chemo-Free » Treatment Association with Idelalisib + Obinutuzumab in Patients with Relapsed/Refractory (R/R) Waldenstrom's Macroglobulinemia (MW), a Filo Trial: Results of the Intermediary Analysis of the Induction Phase

Results of a Phase III Double-Blind Study of the Addition of Tocilizumab Vs. Placebo to Cyclosporin/Methotrexate Gvhd Prophylaxis after HLA-Matched Allogeneic Stem Cell Transplantation

Copanlisib, a PI3K Inhibitor, Demonstrates a Favorable Long-Term Safety Profile in a Pooled Analysis of Patients with Hematologic Malignancies

Early Hyperbilirubinemia Is an Independent Predictor of Outcome after Allogeneic Stem Cell Transplantation and Correlates with Markers of Endothelial Cell Dysfunction

Early Organ Toxicity Following Allogeneic Hematopoietic Stem Cell Transplantation Differs By Conditioning Regimen

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Efficacy and Safety of Daily All-Trans Retinoic Acid Monotherapy As Maintenance Therapy for Acute Promyelocytic Leukemia

Oral Arsenic Trioxide in Front Line Therapy for Acute Promyelocytic Leukemia. A Prospective Costa Rican Study

Transient Elevations in Markers of Hepatic Function during Pediatric Acute Lymphoblastic Leukemia Treatment Are Common but Do Not Influence Outcomes: A Study of 805 Patients from the Learn Consortium

Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only